Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:LG_Chem
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Michael_Bailey
|
| gptkbp:collaboratedWith |
gptkb:Astellas_Pharma
EUSA Pharma |
| gptkbp:developedDrug |
tivozanib
|
| gptkbp:focusesOn |
oncology
|
| gptkbp:formerName |
GenPath Pharmaceuticals
|
| gptkbp:foundedIn |
2002
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aveo Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:product |
AV-203
AV-380 FOTIVDA ficlatuzumab |
| gptkbp:publiclyTraded |
NASDAQ: AVEO
|
| gptkbp:specializesIn |
cancer therapeutics
|
| gptkbp:website |
https://www.aveooncology.com/
|
| gptkbp:bfsParent |
gptkb:Henri_Termeer
|
| gptkbp:bfsLayer |
7
|